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Background: Many aspects of co-morbidity burden in Parkinson’s disease (PD) are unclear, but it may be
an important predictor of prognosis or confounder of associations in epidemiological studies.
Objectives: To determine how best to assess co-morbidity burden in PD, to compare with matched
controls, and investigate its association with prognostic outcomes.
Methods: Data from an incident, community-based cohort with prospective follow-up (the PINE study)
were used (198 patients with PD and 151 controls). The reliability of three co-morbidity scales (the
Charlson co-morbidity index (CCI), the Cumulative Illness Rating scale and a simple disease count) were
evaluated. The association with mortality and development of dependency was assessed with Cox
regression. The co-morbidity burden in PD and controls was compared at baseline and over 5 years of
follow-up using linear mixed modelling.
Results: The CCI was more reliable and was an independent predictor of mortality with a time-
dependent effect (hazard ratio ¼ 1.27 [1.08e1.49] in ﬁrst four years of follow-up; no signiﬁcant associ-
ation after four years). Associations between the other scales and mortality and between each scale and
development of dependency were non-signiﬁcant once adjusted for confounders. Co-morbidity burden
was similar between cases and controls at baseline and there was no evidence of differential accrual of
co-morbidity between patients and controls (p ¼ 0.94).
Conclusions: The CCI is probably the better scale for measuring co-morbidity burden in PD. There were
no differences between PD and controls. Co-morbidity burden at diagnosis was associated with mortality
in the early part of the disease course, but not later.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Parkinson’s disease (PD) predominantly occurs in the elderly [1],
where other illnesses are common. Although certain speciﬁc co-
morbid diseases have been studied in PDdfor example, people
with PD have a lower risk of cancer than in the general population
[2]dvery little is known about the overall co-morbidity burden in
PD. Basic aspects of this are unclear, including whether co-
morbidity burden differs from that of the general population and
how best to measure it in PD. Additionally, although an increase in
overall co-morbidity burden has been shown to increase mortality
and disability in the general population [3,4], its inﬂuence onding, University of Aberdeen,
Macleod).
r Ltd. This is an open access articleprognosis in PD is unclear. In PD, co-morbidity burden may be an
important independent prognostic factor and a confounder of as-
sociations or an effect modiﬁer in epidemiological studies; thus
understanding its inﬂuence on prognosis is important for studies of
prognosis in PD. Measuring overall co-morbidity as a single vari-
able, rather than multiple individual diseases, is necessary for ef-
ﬁciency of statistical analyses [5].
We therefore aimed to determine which scale to use to measure
co-morbidity in PD; to identify whether co-morbidity inﬂuences
prognosis in PD; and compare the overall co-morbidity burden in
PD and controls at diagnosis and during follow-up.
2. Methods
2.1. Study design
The PINE study is an incident cohort of PD and other forms ofunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Scotland [6,7]. Using multiple community-based ascertainment
strategies we tried to identify all new diagnoses of degenerative or
vascular parkinsonism (deﬁned broadly as having at least two
cardinal signs) during two incidence periods totaling 4.5 years
(2002e2004 and 2006e2009). Patients were invited to consent to
long-term follow-up. For each patient recruited, an age- and sex-
matched control was sought from the same general practice. The
only exclusion for patients was drug-induced parkinsonism, but
controls were excluded if they were unable to give informed con-
sent because of dementia or if they were found to be parkinsonian.
Consenting patients and controls were seen annually and un-
derwent comprehensive clinical assessment including de-
mographics, clinical history and examination, review of medical
case notes, and both generic and PD-speciﬁc assessment scales. All
participants were tagged to the NHS central register so that regular
notiﬁcations of deaths were also received. Patients’ diagnoses were
reviewed at each appointment by a neurologist with a special in-
terest in movement disorders or by a supervised trainee. Diagnoses
of PD were guided by the UK PD Brain Bank criteria [8]. Only those
who had a diagnosis of idiopathic PD at latest follow-up, and the
controls matched to these patients, were included in the analyses
described here.
Ethical approval for the PINE study recruitment and follow-up
was obtained from the Grampian Research Ethics Committee and
the Multi-Centre Research Ethics Committee for Scotland. The
participants gave written informed consent and all data were
stored securely.
2.2. Co-morbidity data
Two sources of co-morbidity data were available: research ﬁles
from the PINE study and electronic summaries of primary care
records. The research ﬁles contained information about co-morbid
illness gathered from participants at clinical interview at baseline
(i.e. at diagnosis for patients and at recruitment for controls) and
subsequent visits, and also from review of hospital case notes.
We evaluated three different scales of co-morbidity burden, two
weighted scales (the Charlson co-morbidity index [CCI] [9], the
Cumulative Illness Rating Scale [CIRS]) [10] and a simple un-
weighted disease count. The ﬁrst two of these scales were chosen as
they are commonly used in the epidemiological literature and have
previously been used in PD [5,11e13]. The CCI uses a speciﬁed list of
mostly chronic diseases which areweighted between one and six. It
has been validated in several populations and various diseases
[5,11]. The CIRS counts co-morbid diseases by body system and
includes grading of severity of disease, from zero (no disease, or
previous problems with no sequelae) to four (an extremely severe
problem). It has been shown to be valid and reliable for use in
several situations, including older populations [5,14]. We also used
an unweighted disease count as it is arguably a simpler method of
evaluating co-morbidity and simple counts of disease have previ-
ously been shown to perform similarly to complex measures when
predicting most outcomes, including mortality [11]. For the disease
count we deﬁned a disease as any condition requiring ongoing
treatment or one that causes disordered organ function, after Gross
et al. [15].
2.3. Comparison of co-morbidity scales and investigation of
association with prognostic outcomes
We compared these three scales in PD at baseline only. Using the
available data on co-morbidity, scores were calculated using each
scale. The reliability of the scales was compared by assessing the
intra- and inter-rater reliability with intraclass correlationcoefﬁcients [ICCs]). The ﬁrst 40 cases were scored by one assessor
(HG)who re-scored the ﬁrst 20 of these cases 8 weeks later, blind to
the ﬁrst scoring. A second researcher (ADM) re-scored the other 20
cases, also blind to the ﬁrst scoring.
In order to (i) assess the construct validity of the scales and (ii) to
assess the effect of co-morbidity on prognosis, we investigated the
association between each co-morbidity scale and two important
prognostic outcomes: mortality and dependency. Dependency,
(needing help with basic activities of daily living) was deﬁned as a
sustained score of <80 on the Schwab & England scale [16]. We
ﬁrstly plotted Kaplan-Meier survival probabilities by categories of
each co-morbidity scale. We then performed survival analysis using
Cox regression using data until the end of follow-up. Separate
models were created with each scale in turn as the exposure of
interest (as a continuous variable), for each outcome. We generated
both unadjusted models (univariable associations) and also
adjusted multivariable models by adding potential confounding
variables measured at diagnosis. These potential confounders were
variables likely to be associated with both co-morbidity and mor-
tality: age, sex, smoking status (ever or never), an area-based so-
cioeconomic deprivation measure (DepCat score) [17] and severity
of parkinsonian impairment (Uniﬁed Parkinson’s disease rating
scale [UPDRS] motor score) [18]. The potential confounders were
included in the model irrespective of their statistical signiﬁcance.
Smokingwas not included separately in models with CIRS since it is
scored within this rating scale itself. Patients lost to follow-up, or
those still alive/independent at the time of data extraction from the
study databasewere censored. Patients dependent at baselinewere
excluded from the models of dependency. There were no missing
data for any of the baseline variables in the models.
The proportional hazards assumption was tested by formal
testing based on Schoenfeld residuals [19]. If there was evidence of
violation of the proportional hazards assumption for the co-
morbidity scales, an interaction term between the scale and time
period was added (time divided into two intervals with approxi-
mately similar numbers of events in each). A likelihood ratio test
was used to compare a model with and without this interaction.
Otherwise, interactions were not assessed due to lack of power.
Because we found a time-varying effect of co-morbidity on mor-
tality we reviewed the clinical data available (research records,
hospital case notes, and general practice records where available)
to identify whether the proportion of deaths related to PD (such as
due to general frailty, pneumonia, complications of fractures, or
complications of immobility) varied over time.2.4. Comparison between patients and controls
For comparisons between patients and controls we used only
the CCI as it demonstrated the best reliability andwas the only scale
to be independently associated with mortality. The distribution of
baseline co-morbidity was compared between PD and controls
both graphically and with theWilcoxon rank-sum test. The effect of
time on change in co-morbidity over the ﬁrst ﬁve years of follow-up
was assessed using a linear mixed-model to adjust for repeated
measures. CCI deﬁned the dependent variable, and time (year of
follow-up) was included in the model as the co-variate of interest.
An interaction between patient/control status and time was
included to assess whether change in CCI varied between patients
and controls. Potential confounders (age, sex, and smoking status)
were included as ﬁxed effects in the model. An autoregressive
covariance structure was assumed.
Statistical analyses were performed using Stata version 12.1
(StataCorp, College Station, TX).
A.D. Macleod et al. / Parkinsonism and Related Disorders 28 (2016) 124e1291263. Results
377 incident patients with parkinsonism were identiﬁed in the
incidence phase of the PINE study (see supplementary ﬁgure). Of
the 355 who consented to follow-up, 198 were identiﬁed as having
PD at latest follow-up. 151 age- and sex-matched controls were
recruited for the PD patients (the consent rate in potential controls
approached was 44%). Two cases and one control were lost to
follow-up for co-morbidity between baseline assessment and the
ﬁfth year of follow-up. 57 patients and 22 controls had died by ﬁve
years of follow-up. No patient was lost to follow-up for mortality
data after between 6 and 12 years of follow-up). Thirty patients had
sustained dependency from baseline and a further 6 patients died
before their ﬁrst follow-up visit so were also excluded from the
analyses of survival to development of dependency so 162 were
included in these analyses. Two patients were lost to follow-up for
dependency data. The baseline characteristics of the cases and
controls are summarized in Table 1.3.1. Reliability of scales
The intra- and inter-rater reliability of the three scales are
shown in Table 2. All three scales produced ICCs> 0.9 indicating
excellent intra-rater reliability. The CCI had excellent inter-rater
reliability with an ICC of 0.96 whereas the CIRS and the disease
count had fair and moderate inter-rater reliability, respectively. The
CIRS also took longer to score than the other two scales.3.2. Association with prognostic outcomes
Hazard ratios for associations between the three scales and the
outcomes are displayed in Table 2. There was strong evidence that
the association between the baseline CCI and mortality varied over
time (p ¼ 0.01, test based on Schoenfeld residuals) but the pro-
portional hazards assumption was satisﬁed when an interaction
between time period and CCI was added, and this interaction
resulted in better ﬁt (p¼ 0.007). Fig. 1 shows Kaplan-Meier survival
curves for different levels of the CCI. Therewas strong evidence that
a higher baseline CCI was associated with higher mortality during
the ﬁrst four years of follow-up (HR 1.27 [1.08e1.49]), but therewas
no evidence of an association in the second period of follow-up (HR
0.84 [0.64e1.10]). There was corroborative evidence for this ﬁnding
from the analysis of whether deaths were related to PD, which
showed an increasing proportion of deaths related to PD over time:
15% before two years, 47% between two and four years, 58% be-
tween 4 and 6 years, and 69% between 6 and 8 years. Whilst CIRS
and disease counts were associated with mortality in theTable 1
Baseline characteristics of patients with Parkinson’s disease and matched
Baseline variable Parkinson’s
Mean age (SD) 72.5 (10.4)
Male sex, n (%) 119 (60)
Ever smoked, n (%) 89 (45)
UPDRS Motor Score, mean (SD) 25.1 (11.6)
DepCat Scorea
1e2 106 (54)
3e4 54 (27)
5e6 38 (19)
Presence of any tremor, n (%) 170 (86)
SE-ADL 90 (80e9
a 1 most afﬂuent, 6 most deprived.
b 6 missing data.
c 4 missing data.
d 6 missing data.univariable analyses (but with a less strong association than with
the CCI) there was no evidence that they were independently
predictive of mortality after adjustment for potential confounders
(Table 2). Age was the key confounder leading to the apparent as-
sociation in the univariable analyses. There was no robust evidence
that any co-morbidity scale was associated with dependency after
adjustment for confounders. Age, again, was the confounding var-
iable which led to the stronger effect in the crude analyses.3.3. Comparison between PD and controls
The distribution of Charlson scores in PD and controls at base-
line is shown in Fig. 2A. There was no evidence of a difference
between the patients and controls (p ¼ 0.57, Wilcoxon rank-sum
test). The mean increase in CCI in all participants was 0.13 points
per year. Change over time in patients and controls is displayed
graphically in Fig. 2B. There was no evidence that there was a
different rate of accumulation of co-morbidity between patients
and controls in the mixed model (p ¼ 0.94).4. Discussion
All the scales had good intra-rater reliability, but the CCI had
better inter-rater reliability for co-morbidity measurement in PD.
The CCI was also quicker to score than the CIRS. Furthermore, the
CCI was the only scale that was independently predictive of mor-
tality in PD. This is the ﬁrst study to compare different scales for the
measurement of overall co-morbidity burden in PD and these fac-
tors suggest that the CCI may be preferable for use in future studies
in PD. It is likely that the CCI has better inter-rater reliability
because (i) it speciﬁes precisely which diseases are to be included
so is less subjective than the other scales, especially the CIRS which
includes assessment of disease severity; and (ii) because there is
less variation in the scoring than in the other scales.
It is unclear why the other two scales were not predictive of
mortality. Only one previous study has published data on the as-
sociation between baseline co-morbidity and mortality in PD
[20,21]. It found that cardiac co-morbidities (but not other types of
co-morbidity) were associated with mortality. One study in PD
showed that the overall co-morbidity burden was associated with
poorer outcomes in terms of disability and quality of life [13], but no
previous study has reported the association between overall co-
morbidity burden and mortality in PD or in other parkinsonian
disorders. The diseases comprising the CCI were selected according
to their association with mortality [9], which may explain why it
would have a stronger association with mortality than the other
scales, but it is surprising that no independent association wascontrols.
disease (N ¼ 198) Controls (N ¼ 151)
73.6 (9.8)
96 (64)
95 (63)
3.3 (3.8)b
76 (50)
40 (26)
35 (23)
19 (13)c
5) 100 (95e100)d
Table 2
Reliability and associations with prognostic outcomes of three co-morbidity scales in Parkinson’s disease.
Scale Reliability Association with mortalityb Association with dependencyc
Type of
reliability
ICC (95% CI)a Crude hazard ratio (95%
CI)
Adjusted hazard ratio (95% CI) Crude hazard ratio (95%
CI)
Adjusted hazard ratio (95%
CI)
Charlson Intra-rater 0.98 (0.96e0.99) 1.30 (1.15e1.49) First four years: 1.27 (1.08e1.49)d
After four years: 0.84 (0.64
e1.10)d
1.25 (1.09e1.44) 1.10 (0.95e1.26)d
Inter-rater 0.96 (0.91e0.99)
CIRS Intra-rater 0.99 (0.95e1.00) 1.07 (1.01e1.12) 1.00 (0.95e1.06)e 1.10 (1.05e1.16) 1.03 (0.98e1.09)e
Inter-rater 0.40 (0.10e0.74)
Disease
Count
Intra-rater 0.96 (0.91e0.99) 1.10 (1.00e1.20) 0.98 (0.88e1.08)d 1.18 (1.08e1.29) 1.05 (0.95e1.16)d
Inter-rater 0.62 (0.11e0.85)
a N ¼ 20 for each reliability comparison.
b N ¼ 198 for analyses of association with mortality.
c N ¼ 162 for analyses of association with dependency.
d Adjusted for age, sex, deprivation score, smoking status, and UPDRS motor score.
e Adjusted for age, sex, deprivation score, and UPDRS motor score. Abbreviations: ICC ¼ intraclass correlation co-efﬁcient; CI ¼ conﬁdence interval; CIRS ¼ cumulative
illness rating scale.
Fig. 1. Kaplan-Meier survival probabilities in Parkinson’s disease by baseline Charlson index. Black vertical marks represent censored observations.
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nesses included in the other two scales do not have a strong as-
sociation with mortality which dilutes the effect of those illnesses
which are associated with increased mortality. Lack of power is a
possible explanation for the lack of evidence of an association be-
tween other scales and mortality.
Our ﬁnding that co-morbidity burden was strongly associated
with mortality in the ﬁrst period of follow-up, but was not asso-
ciated in the later period, is novel. This is probably because, as our
data shows, early deaths in PD are more likely to be related to other
diseases than due to PD itself as PD is not usually rapidly pro-
gressive [8]. By contrast, later deaths in PD aremore likely to be due
to complications of PD itself or co-morbidity which developed after
diagnosis. It is therefore important to adjust for baseline co-
morbidity in prognostic studies of short-term outcomes, whereas,
if long-term outcomes are of more interest, measurement of, and
adjustment for, accrued rather than baseline co-morbidity may bemore important.
We did not ﬁnd any association between baseline co-morbidity
and the development of functional dependency. No previous
studies have investigated the association between co-morbidity
and dependency [22], and the only study which has investigated
co-morbidity burden as a prognostic factor in terms of disability in
general found that it was independently predictive on one measure
of disability but not another [13]. It is likely that the burden of co-
morbidity is therefore much less important in terms of the devel-
opment of dependency that factors related to PD itself.
We found no signiﬁcant difference in overall baseline co-
morbidity burden between cases and controls and no difference
in the accrual of co-morbidity over time. Two previous studies also
showed similar co-morbidity burden in PD and controls [12,23].
Conversely, one study reported about twice as much co-morbidity
in PD than in controls [24], but in that study, the mean age in pa-
tients was 69, compared to 45 in controls, and the confounding
Fig. 2. A: Distribution of baseline Charlson scores in Parkinson’s disease and in controls. B: Mean Charlson scores from linear mixed model in Parkinson’s disease and in controls
over ﬁve years. Error bars represent 95% conﬁdence intervals.
A.D. Macleod et al. / Parkinsonism and Related Disorders 28 (2016) 124e129128effect of age was not adjusted for in the analyses. This is the ﬁrst
study to report the accrual of co-morbidity in PD, and to compare
this with controls. As dementia is included in the Charlson, and is
commoner in PD that in controls, we expected the rise in co-
morbidity burden to be greater, but we did not ﬁnd this, maybe
because we analysed data only up to ﬁve years, at which time most
patients have not developed dementia.
This study has several strengths. Firstly, recruitment of patients
had low risk of selection bias. Patients were recruited from the
community, were recruited at the time of their diagnosis, and,
furthermore, as the cohort was derived from an incident study we
attempted to recruit all new patients with PD in the geographical
area in the incident period. Additionally, there was a high consent
rate to follow-up and very few losses to follow-up. Secondly, con-
trol recruitment was community-based and controls were age-sex
matched to patients. Thirdly, we had access to comprehensive co-
morbidity data (including primary care record summaries) and
were able to verify participants’ self-report. Similarly, data on death
were comprehensive and accurate. Fourthly, we strove to analyze
the data carefully, with adjustment for confounding and for cor-
relation due to repeated measurements, where appropriate, and
avoided including toomany variables in the models. In terms of the
association with prognostic outcomes this study meets the criteria
previously recommended for prognostic factors studies [25].
Nevertheless, there are some limitations to this study. While
therewas adequate sample size for comparisons between cases and
controls, there was limited power for identiﬁcation of weak asso-
ciations with outcomes. Selection bias in control recruitment is
possible as the consent rate amongst approached controls was 44%.
While not an unusually low consent rate, it has the potential to
introduce selection bias. We previously investigated this possibility
and found that consenting controls were broadly similar to those
approached who did not consent, but that the consenters scored
slightly worse on some health-relatedmetrics [26]. In the ﬁve years
over which the change in mortality was studied, the risk of death
was higher in patients than in controls. Although a linear mixed
model can handle missing data, assuming it is missing at random,
the differential rate of death may introduce bias [27].These ﬁndings are important for future prognostic studies in PD.
Co-morbidity is an independent prognostic factor and may there-
fore be a confounder in the relationship between other prognostic
factors and outcome in PD. Further work is needed to examine the
relationship between co-morbidity burden and other prognostic
factors. For instance, aspects of social support may be important
inﬂuences on the relationship between co-morbidity and outcome.
These data suggest a very weak effect of co-morbidity burden on
dependency, but this may be due to chance and a larger study with
more power may be able to estimate this more precisely. Co-
morbidity burden should also be included in prognostic models
of outcome in PD, which may be useful in predicting individual
outcomes or in clinical research for case-mix correction or for
stratifying randomization in clinical trials.
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